Selected fourth quarter clinical and regulatory setbacks.



AB Science S.A. (Euronext:AB)

Masitinib plus Gemzar gemcitabine from Eli Lilly and Co. (NYSE:LLY) fails in a Phase III trial to treat pancreatic cancer

Allon Therapeutics Inc. (TSX:NPC)

Davunetide administered as a nasal spray fails a Phase II/III trial to treat progressive supranuclear palsy

Amicus Therapeutics Inc. (NASDAQ:FOLD)/GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

Amigal migalastat fails the Phase III FACETS (Study 011) trial to treat Fabry's disease

Angiochem Inc./Geron Corp. (NASDAQ:GERN)

Discontinues development of GRN1005 after the compound produced no confirmed intracranial responses in the Phase II GRABM-B trial to treat brain metastases arising from metastatic breast cancer

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)/Merck & Co. Inc. (NYSE:MRK)

Withdraw MAA for ridaforolimus as maintenance therapy for patients with soft tissue sarcoma or primary malignant bone tumor

ArQule Inc. (NASDAQ:ARQL)/Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568)/Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151)

Discontinue Phase III MARQUEE trial to treat NSCLC after analysis shows tivantinib plus Tarceva erlotinib will miss the primary endpoint; later in the quarter the partners discontinue the Asian Phase III ATTENTION trial of tivantinib in NSCLC based on a recommendation by the trial's safety committee